Spectrum Pharmaceuticals Licenses Belinostat to TopoTarget

Spectrum Pharmaceuticals has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor. Belinostat is in a registrational trial, under a Special Protocol Assessment (SPA), as a monotherapy for relapsed or refractory Peripheral T-Cell Lymphoma (PTCL), an indication in which it has been granted Orphan Drug and Fast Track designations by the FDA. Belinostat is also under investigation in a randomized Phase II trial, as a combination therapy with carboplatin and paclitaxel, for the cancer of unknown primary (CUP).

Under the terms of the agreement, Spectrum licensed the rights to TopoTarget A/S for North America and India and gave an option for China, in exchange for an upfront cash payment of $30 million, potential milestone payments of up to $320 million, and 1 million shares of its common stock based on the successful achievement of certain development, regulatory, and commercial milestones, as well as double-digit royalties on net sales of Belinostat. Spectrum and TopoTarget will jointly fund development activities: 70% of the clinical trial costs will be borne by Spectrum and 30% by TopoTarget for new trials.

Source: Spectrum

 

Abbott and Pierre Fabre to Develop and Commercialize Pre-clinical mAb

Abbott has signed an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody (mAb) targeting the cMet receptor, for treatment of cancer. As part of the agreement, the companies will also collaborate on research to explore next-generation cMet antibodies. Under the terms of the agreement, Abbott will lead the development and commercialization of mAb. Pierre Fabre SA will receive an initial upfront payment of $25 million and research funding for two years to support further discovery efforts.

Source: Abbott

 

Tenx Biopharma Licenses Zanolimumab from Genmab

TenX Biopharma has signed a licensing agreement to acquire exclusive worldwide rights from Genmab to develop and commercialize zanolimumab (HuMax-CD4), a fully human monoclonal IgG1k antibody, for treatment of cutaneous and peripheral T cell lymphoma. Under the terms of the agreement, Genmab will receive an upfront license fee of $4.5 million and will be entitled to milestones and royalties on sales of zanolimumab. TenX will be responsible for all the future costs of developing, manufacturing, and commercializing zanolimumab. "Zanolimumab has promise for treatment of patients with T cell cancers, and potential in other cancer types for which existing therapies are inadequate. We are building a pipeline of new medicines for high unmet need, with a focus on the patient through business efficiency," said Gardiner F.H. Smith, CEO of TenX Biopharma. 

Source: Tenx Biopharma

 

BioMarin to Acquire LEAD Therapeutics

BioMarin Pharmaceutical has entered into a stock purchase agreement to acquire LEAD Therapeutics (LEAD), with a key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor, for treatment of patients with rare, genetically defined cancers. Under the terms of the agreement, BioMarin will pay $18 million upfront to LEAD’s stockholders and an additional $11 million upon the acceptance of the IND filing (filing expected by end of 2010), and up to $68 million for development and launch milestones for LT-673. With this acquisition, BioMarin expects to incur operating expenses and acquisition-related charges of about $11.0-13.0 million in 2010. Subject to customary closing conditions, the acquisition is expected to be completed by mid-February 2010.

Source: BioMarin

 

3SBio and Ascentage Pharma to Develop, and Commercialize Cancer Therapeutics

3SBio and Ascentage Pharma Group Corporation announced the formation of a strategic alliance to research, develop, and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization, and preclinical development with 3SBio's proven drug development and commercialization capabilities in China. Under the terms of the agreement, 3SBio will make a $3 million equity investment in Ascentage Pharma to fund R&D programs. 3SBio will have the exclusive rights to develop and commercialize cancer therapeutics, in China, which are discovered through Ascentage Pharma programs, while Ascentage Pharma will retain the rights for the rest of the world and receive future milestone and royalty payments from 3SBio’s sales in China.

Source: 3SBio

 

Back to top